VIVUS — Technical Presentation (October 2009)
27 slides from VIVUS's technical presentation, Oct 26, 2009
Slide 1: Qnexa Pharmacotherapy Update
Copyright © 2009 VIVUS Inc. All rights reserved. | www.vivus.com Qnexa Pharmacotherapy Update October 24, 2009 Wesley W. Day VP Clinical Development VIVUS Inc.
Slide 2: Qnexa: Proprietary Investigational Treatment for Obesity
Copyright © 2009 VIVUS Inc. All rights reserved. | www.vivus.com 400 mg Qnexa: Proprietary Investigational Treatment for Obesity • Once-a-day, oral, controlled-release formulation of low dose phentermine and topiramate • Specifically designed to impact normal eating patterns over 24 hours - simultan
Slide 3: EQUIP & CONQUER Study Designs: Primary Study Endpoints
Copyright © 2009 VIVUS Inc. All rights reserved. | www.vivus.com EQUIP & CONQUER Study Designs: Primary Study Endpoints Co-Primary Endpoints (at 1 year) • Mean percent weight loss • The difference in mean percent loss of baseline body weight in the active-product versus placebo-treated group • Categ
Slide 4: EQUIP & CONQUER: Study Entry Criteria
Copyright © 2009 VIVUS Inc. All rights reserved. | www.vivus.com EQUIP & CONQUER: Study Entry Criteria • Adults <70 years of age • BMI >35 • Blood pressure <140/90 mmHg using 0-2 antihypertensive medications • Fasting blood glucose < 110 mg/dL • Triglycerides <200mg/dL using 0 or 1 lipid lowering me
Slide 5: Study Design
Copyright © 2009 VIVUS Inc. All rights reserved. | www.vivus.com EQUIP (N=1,267): Morbidly Obese Subjects CONQUER (N=2,487): Obese with Comorbidities Titration (4 weeks) Treatment (52 weeks) EQUIP/CONQUER Treatment Week: Qnexa Full Dose (n=512)/(n=995) Qnexa Low Dose (n=241) EQUIP Placebo (n=514)/(n
Slide 6: EQUIP: Co-Primary Efficacy Endpoints
Copyright © 2009 VIVUS Inc. All rights reserved. | www.vivus.com Placebo Qnexa Low Qnexa Full EQUIP: Co-Primary Efficacy Endpoints *p<0.0001 vs. placebo Mean Percent Wt Loss Mean % Weight Loss at Week 56 (ITT-LOCF) n=498 n=234 n=498 -1.6 -5.1 -11.0 -12.0 -9.0 -6.0 -3.0 0.0 * * % Patients Achieving >
Slide 7: EQUIP: Percent Weight Loss by BMI Category (ITT-LOCF)
Copyright © 2009 VIVUS Inc. All rights reserved. | www.vivus.com EQUIP: Percent Weight Loss by BMI Category (ITT-LOCF) 1.8 1.3 1.0 1.1 10.7 11.1 11.2 5.0 5.9 4.3 5.5 11.8 0 2 4 6 8 10 12 >35 - 40 >40 -45 >45 - 50 >50 Placebo Qnexa Low Qnexa Full % Weight Loss Baseline BMI Category *p<0.05 vs. placeb
Slide 8: EQUIP: Continuing Weight Loss Over Time
Copyright © 2009 VIVUS Inc. All rights reserved. | www.vivus.com EQUIP: Continuing Weight Loss Over Time Completers* Lost 14.7% Body Weight - Qnexa Low -7.0%, 18 lbs - Placebo -2.5%, 6 lbs - Qnexa Full -14.7%, 37 lbs Mean % Weight Loss Weeks Patients Placebo Low Full Completers (% of randomized) 241
Slide 9: EQUIP: Significant Categorical Weight Loss with Qnexa Low or Full Dose
Copyright © 2009 VIVUS Inc. All rights reserved. | www.vivus.com EQUIP: Significant Categorical Weight Loss with Qnexa Low or Full Dose 0 10 20 30 40 50 60 70 80 90 5% 10% 15% % of Patients Qnexa Full Qnexa Low PBO % of Patients with: • >15% wt loss PBO 5% Qnexa Low 11%* Qnexa Full 43%** • >10% wt l
Slide 10: EQUIP: Greater Weight Loss Linked to Broader Improvement Across CV Risk Factors
Copyright © 2009 VIVUS Inc. All rights reserved. | www.vivus.com EQUIP: Greater Weight Loss Linked to Broader Improvement Across CV Risk Factors CV Risk Factors (Mean % Wt Loss) Qnexa Low (5.1%) p-value* Qnexa Full (11.0%) p-value* Waist Circumference <0.0001 <0.0001 Systolic BP 0.002 <0.0001 Diasto
Slide 11: OB-303 CONQUER: Effect of Qnexa in Co-Morbid Obese
Copyright © 2009 VIVUS Inc. All rights reserved. | www.vivus.com OB-303 CONQUER Effect of Qnexa in Co-Morbid Obese
Slide 12: CONQUER: Co-Primary Efficacy Endpoints
Copyright © 2009 VIVUS Inc. All rights reserved. | www.vivus.com -1.8 -8.4 -10.4 -12 -9 -6 -3 0 21 62 70 0 10 20 30 40 50 60 70 80 CONQUER: Co-Primary Efficacy Endpoints *p<0.0001 vs. placebo % of Patients * * Placebo Qnexa Low Qnexa Full Mean % Weight Loss at Week 56 (ITT-LOCF) n=979 n=488 n=981 %
Slide 13: CONQUER: Weight Loss Over Time
Copyright © 2009 VIVUS Inc. All rights reserved. | www.vivus.com - Qnexa Mid -10.5%, 24 lbs CONQUER: Weight Loss Over Time Completers* Lost 13.2% Body Weight - Qnexa Full -13.2%, 30 lbs - Placebo 2.4%, 6 lbs Mean % Weight Loss Weeks 42%2 excess body weight loss Patients Placebo Mid Full Completers (
Slide 14: CONQUER: Significant Categorical Weight Loss with Qnexa Mid or Full Dose
Copyright © 2009 VIVUS Inc. All rights reserved. | www.vivus.com CONQUER: Significant Categorical Weight Loss with Qnexa Mid or Full Dose 0 10 20 30 40 50 60 70 80 90 5% 10% 15% % of Patients Qnexa Full Qnexa Mid PBO % of Patients with: • >15% wt loss PBO 4% Qnexa Mid 26%** Qnexa Full 39%** • >10% w
Slide 15: CONQUER: Improved Cardiovascular Risk Factors
Copyright © 2009 VIVUS Inc. All rights reserved. | www.vivus.com CONQUER: Improved Cardiovascular Risk Factors Risk Factors (Mean % Wt Loss) Qnexa Mid (8.4%) p-value Qnexa Full (10.4%) p-value Waist Circumference <0.0001 <0.0001 Systolic BP <0.0001 <0.0001 Diastolic BP ns 0.0031 Triglycerides <0.000
Slide 16: CONQUER: Decreased BP in Obese Hypertensive Patients
Copyright © 2009 VIVUS Inc. All rights reserved. | www.vivus.com -5.6 -8.3 -7.0 -10 -8 -5 -3 0 Placebo Qnexa Mid Qnexa Full 3.4 10.5 6.6 12 10 8 6 4 2 0 2 4 6 Placebo Qnexa Mid Qnexa Full *p=0.0475 vs placebo **p<0.0001 vs. placebo Baseline SBP 135.0 134.0 133.0 SBP (mmHg) ** * SBP Change at Week 56
Slide 17: CONQUER: Improved Diabetes Risk Factors
Copyright © 2009 VIVUS Inc. All rights reserved. | www.vivus.com CONQUER: Improved Diabetes Risk Factors Risk Factors Qnexa Mid p-value Qnexa Full p-value Hemoglobin A1c <0.0001 <0.0001 Fasting Blood Glucose 0.0047 <0.0001 OGTT Insulin 0.0007 <0.0001 Insulin Resistance (HOMA) <0.0001 <0.0001 p-value
Slide 18: CONQUER: Decreased HbA1c in Obese Diabetic Patients
Copyright © 2009 VIVUS Inc. All rights reserved. | www.vivus.com -0.1 -0.4 -0.4 -0.45 -0.40 -0.35 -0.30 -0.25 -0.20 -0.15 -0.10 -0.05 0.00 Placebo Qnexa Mid Qnexa Full 12.1 0.6 1.5 0 2 4 6 8 10 12 14 Placebo Qnexa Mid Qnexa Full CONQUER: Decreased HbA1c in Obese Diabetic Patients • Rates of hypoglyc
Slide 19: EQUIP & CONQUER Safety and Tolerability
Copyright © 2009 VIVUS Inc. All rights reserved. | www.vivus.com EQUIP & CONQUER Safety and Tolerability
Slide 20: EQUIP & CONQUER: Adverse Events >5%
Copyright © 2009 VIVUS Inc. All rights reserved. | www.vivus.com EQUIP & CONQUER: Adverse Events >5% EQUIP (N=1,264) CONQUER (N=2,485) % of Patients Placebo Qnexa Low Qnexa Full Placebo Qnexa Mid Qnexa Full Dry Mouth 3.7 6.7 17.0 2.4 13.5 20.8 Tingling 1.9 4.2 18.8 2.0 13.7 20.5 Constipation 6.8 7.9
Slide 21: Discontinuation Rate in All Doses Studied
Copyright © 2009 VIVUS Inc. All rights reserved. | www.vivus.com Discontinuation Rate in All Doses Studied Placebo Qnexa Low Qnexa Mid Qnexa Full Number of Subjects 1,508 241 498 1,507 Study Completion 53% 57% 69% 62% Discontinuation due to AEs 9% 12% 12% 18% Blurred Vision 0.5% 2.1% 0.8% 0.7% Heada
Slide 22: EQUIP & CONQUER: Depression Assessment
Copyright © 2009 VIVUS Inc. All rights reserved. | www.vivus.com EQUIP & CONQUER: Depression Assessment Placebo Qnexa Low Qnexa Mid Qnexa Full Moderate or severe AEs of Depression/Depressed Mood 1.7% 1.7% 1.2% 1.9% • 26-30% of patients had a history of psychiatric disorders at baseline • No serious
Slide 23: EQUIP & CONQUER: Suicidality Assessments
Copyright © 2009 VIVUS Inc. All rights reserved. | www.vivus.com EQUIP & CONQUER: Suicidality Assessments 0.0% 0.0% 0.0% 0.0% 0.0% Ideation (with intent) Placebo N=1,506 Qnexa Low N=240 Qnexa Mid N=498 Qnexa Full N=1,505 Qnexa All Doses N=2,243 C-SSRS C-SSRS Composite 0.0% 0.0% 0.0% 0.0% 0.0% Suicid
Slide 24: EQUIP & CONQUER: Discontinuation for Cognitive Events
Copyright © 2009 VIVUS Inc. All rights reserved. | www.vivus.com EQUIP & CONQUER: Discontinuation for Cognitive Events 0.3% 0.0% 0.0% 0.2% 0.0% 0.0% Aphasia (word finding difficulties) EQUIP (N=1,264) CONQUER (N=2,485) % of Patients Placebo Qnexa Low Qnexa Full Placebo Qnexa Mid Qnexa Full Disturban
Slide 25: EQUIP & CONQUER: Serious Adverse Events Attributed to Study Drug by Investigator
Copyright © 2009 VIVUS Inc. All rights reserved. | www.vivus.com EQUIP & CONQUER : Serious Adverse Events Attributed to Study Drug by Investigator Placebo (n=1,508) Qnexa (n=2,243) Rate of SAEs 0.4% 0.4% Description Chest Pain Cholelithiasis Gastric Ulcer Pulmonary Embolism Syncope Uncontrolled Hype
Slide 26: EQUIP & CONQUER: Effects on Blood Pressure & Heart Rate
Copyright © 2009 VIVUS Inc. All rights reserved. | www.vivus.com EQUIP & CONQUER: Effects on Blood Pressure & Heart Rate EQUIP (OB-302) CONQUER (OB-303) Placebo Qnexa Low Qnexa Full Placebo Qnexa Mid Qnexa Full Change in Systolic BP at wk 56 (mmHg)* -0.1 -0.9 -2.1 -3.1 -5.2 -5.6 Change in Diastolic
Slide 27: Qnexa Summary
Copyright © 2009 VIVUS Inc. All rights reserved. | www.vivus.com Qnexa Summary • Unprecedented weight loss 14.7% (37 lbs) • Clinically meaningful improvements across cardiovascular and metabolic risk factors in ITT population • Low, Mid and Full doses of Qnexa exceeded FDA efficacy benchmarks for we